title: The synergistic efficacy of adalimumab and pamidronate in a patient with ankylosing spondylitis.
abstract: A patient with ankylosing spondylitis, after demonstrating incomplete clinical response to adalimumab, received three monthly infusions of pamidronate along with continuing TNF-alpha blockade. Complete disappearance of the back pain was reported after the second pamidronate infusion. The perspectives of the combination therapy with TNF-alpha inhibitor and pamidronate are discussed.
authors.affiliation: Department of Internal Medicine A, Bnai Zion Medical Center, Ruth & Bruce Rappaport Faculty of Medicine, Technion, Haifa, 31048, PO Box 4940, Israel. gslobodin@yahoo.com
authors.forename: Gleb
authors.initials: G
authors.lastname: Slobodin
authors.forename: Itzhak
authors.initials: I
authors.lastname: Rosner
authors.forename: Doron
authors.initials: D
authors.lastname: Rimar
authors.forename: Nina
authors.initials: N
authors.lastname: Boulman
authors.forename: Michael
authors.initials: M
authors.lastname: Rozenbaum
authors.forename: Majed
authors.initials: M
authors.lastname: Odeh
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004164:Diphosphonates / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D000077268:Pamidronate; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004164:Diphosphonates; D000068879:Adalimumab; D000077268:Pamidronate